Association of Zinc with Anemia.
Sen-Shyong Jeng, Yen-Hua Chen
https://pubmed.ncbi.nlm.nih.gov/36432604/Actively Recruiting
Led by University of Florida · Updated on 2026-05-15
25
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating whether zinc supplementation can extend the benefits of botulinum toxin type A Botox injections in adults with cervical dystonia. This randomized, single-blind, crossover placebo-controlled trial focuses on patients who have been receiving regular Botox injections with good response. The study aims to assess the effectiveness, safety, and impact on quality of life and function for cervical dystonia patients receiving zinc citrate compared to a placebo. Participants will take either zinc citrate 30 mg or a matching placebo daily for three months, then switch to the other treatment for another three months. Botox injections will be administered every three months following their usual schedule. Blood tests will be conducted at the start and end of the study to measure zinc, vitamin B12 levels, and other health markers. During the six-month study period, participants will visit the clinic every three months for Botox injections, evaluations, and surveys about symptoms, pain, quality of life, and function. Researchers will monitor the duration of Botox effectiveness and overall safety throughout the trial. The study includes about 20 cervical dystonia patients aged 18 to 89 currently receiving Botox treatment.
CONDITIONS
Zinc as an Adjunctive Therapy for Cervical Dystonia
J
Julie Segura, BA
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of Florida
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Zinc citrate plus botulinum toxin | Placebo plus botulinum toxin |
|---|---|---|
| What it is | Oral zinc citrate 30 mg daily taken alongside ongoing regular botulinum toxin type A injections. | Placebo tablets taken alongside ongoing regular botulinum toxin type A injections. |
| Role in trial | Investigational supplement being evaluated for its effects on botulinum toxin treatment duration and other patient outcomes. | Comparator condition, with placebo supplement to assess effects relative to zinc supplementation, under ongoing botulinum toxin treatment. |
| Primary use | Studied as an add-on to prolong duration of botulinum toxin effect and improve pain, function, and quality of life in cervical dystonia. | Serves as matched comparator to evaluate effectiveness and safety of zinc supplementation during botulinum toxin therapy. |
| How it is given or performed | Participants take oral zinc citrate 30 mg once daily during the assigned period of the crossover protocol, while continuing regular injections of botulinum toxin type A. | Participants take oral placebo once daily during the assigned period, also while continuing regular injections of botulinum toxin type A. |
| Evidence status | Ongoing phase 2 clinical trial; evidence for zinc supplementation as adjunct to botulinum toxin is not yet established in cervical dystonia. Prior systematic review notes mixed evidence for zinc's adjunctive benefit in botulinum toxin treatment but limited studies address cervical dystonia specifically. | Placebo condition reflects current practice of using botulinum toxin injection alone for cervical dystonia. There is substantial high-quality evidence supporting botulinum toxin as an effective standard of care for cervical dystonia, with established benefit for symptoms and function. |
| Important limitations | Potential benefit of zinc in conjunction with botulinum toxin is not established and evidence is limited, especially for cervical dystonia. Small trial size and crossover design may limit generalizability. Possible risks of zinc supplementation include gastrointestinal upset and, at higher doses, potential for toxicity. | Placebo phase controls for the effect of adding a supplement but does not represent a different treatment strategy from standard care. Usual limitations of crossover design and small clinical trials apply. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Screening and enrollment visit
Duration - 6 months
Participants receive either zinc citrate 30 mg daily or placebo starting immediately after their scheduled botulinum toxin injection. After 3 months, participants switch to the alternative treatment for another 3 months.
2 treatment periods of 3 months each, with scheduled botulinum toxin injections every 3 months
Duration - At baseline and at 6 months
Blood serum levels of zinc and vitamin B12, and complete blood counts (CBCs) are measured at baseline and at the end of the study to monitor participant health and study outcomes.
2 blood draw visits (baseline and end of study)
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Sen-Shyong Jeng, Yen-Hua Chen
https://pubmed.ncbi.nlm.nih.gov/36432604/John C Koshy, Safa E Sharabi, Evan M Feldman...
https://pubmed.ncbi.nlm.nih.gov/22453589/Farid Mallat, Jerome Kaikati, Elio Kechichian
https://pubmed.ncbi.nlm.nih.gov/37335837/Ayse Betul Ergul, Cem Turanoglu, Cigdem Karakukcu...
https://pubmed.ncbi.nlm.nih.gov/30095365/Nesma Shemais, Azza Ezz Elarab, Hani ElNahass
https://pubmed.ncbi.nlm.nih.gov/33950373/University of Florida
Lead Sponsor